TILs, Olutasidenib, T-DXd
from OncoPharm Hosted by John Bossaer
Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice. Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1). A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 17 minutes long.
When was this OncoPharm episode published?
This episode was published on December 8, 2022.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.